• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于共价半胱氨酸蛋白酶抑制剂筛选的新型实验性核磁共振策略的开发:迈向增强药物发现

Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.

作者信息

Chihab Abdelali, El Brahmi Nabil, Hamdoun Ghanem, El Abbouchi Abdelmoula, Ghammaz Hamza, Touil Nadia, Bousmina Mostafa, El Fahime Elmostafa, El Kazzouli Saïd

机构信息

Euromed University of Fes, UEMF Morocco

Centre National de la Recherche Scientifique et Technique (CNRST) Angle avenues des FAR et Allal El Fassi, Hay Ryad 10102 Rabat Morocco.

出版信息

RSC Adv. 2024 Aug 23;14(37):26829-26836. doi: 10.1039/d4ra04938a. eCollection 2024 Aug 22.

DOI:10.1039/d4ra04938a
PMID:39184001
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11342919/
Abstract

In the development of antiviral drugs, proteases and polymerases are among the most important targets. Cysteine proteases, also known as thiol proteases, catalyze the degradation of proteins by cleaving peptide bonds using the nucleophilic thiol group of cysteine. As part of our research, we are examining how cysteine, an essential amino acid found in the active site of the main protease (M) enzyme in SARS-CoV-2, interacts with electrophilic groups present in ethacrynic acid (EA) and compounds 4, 6, and 8 to form sulfur-carbon bonds. Nuclear magnetic resonance (NMR) spectroscopy was used to monitor the reaction rate between cysteine and Michael acceptors. We found that the inhibitory activity of these compounds towards M is correlated to their chemical reactivity toward cysteine. This approach may serve as a valuable tool in drug development for detecting potential covalent inhibitors of M and other cysteine proteases.

摘要

在抗病毒药物的研发中,蛋白酶和聚合酶是最重要的靶点之一。半胱氨酸蛋白酶,也称为硫醇蛋白酶,通过利用半胱氨酸的亲核硫醇基团裂解肽键来催化蛋白质降解。作为我们研究的一部分,我们正在研究半胱氨酸(一种在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(M)酶活性位点中发现的必需氨基酸)如何与依他尼酸(EA)以及化合物4、6和8中存在的亲电基团相互作用以形成硫-碳键。核磁共振(NMR)光谱用于监测半胱氨酸与迈克尔受体之间的反应速率。我们发现这些化合物对M的抑制活性与其对半胱氨酸的化学反应性相关。这种方法可能成为药物研发中检测M和其他半胱氨酸蛋白酶潜在共价抑制剂的有价值工具。

相似文献

1
Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.用于共价半胱氨酸蛋白酶抑制剂筛选的新型实验性核磁共振策略的开发:迈向增强药物发现
RSC Adv. 2024 Aug 23;14(37):26829-26836. doi: 10.1039/d4ra04938a. eCollection 2024 Aug 22.
2
Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an study.估算 SARS-CoV-2 主蛋白酶可逆共价抑制剂的结合能:一项研究。
Phys Chem Chem Phys. 2022 Oct 5;24(38):23391-23401. doi: 10.1039/d2cp03080b.
3
Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M by targeting the cysteine 145.基于对接的虚拟筛选研究旨在通过靶向 SARS-CoV-2 M 的半胱氨酸 145 来实现对其共价抑制。
Comput Biol Chem. 2021 Jun;92:107463. doi: 10.1016/j.compbiolchem.2021.107463. Epub 2021 Feb 20.
4
An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M) of SARS-COV-2 from crude natural extracts.一种从粗天然提取物中鉴定 SARS-CoV-2 主要蛋白酶(M)共价抑制剂的整合代谢组学和蛋白质组学方法。
Talanta. 2023 Jan 15;252:123824. doi: 10.1016/j.talanta.2022.123824. Epub 2022 Aug 12.
5
In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.基于药效团模型和共价对接的联合结构虚拟筛选策略,针对 SARS-CoV-2 主要蛋白酶进行计算机药物重定位以作为共价抑制剂。
Int J Mol Sci. 2022 Apr 3;23(7):3987. doi: 10.3390/ijms23073987.
6
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.将严重急性呼吸综合征冠状病毒2(SARS-CoV-2)蛋白酶作为治疗2019冠状病毒病(COVID-19)的治疗策略所面临的挑战。
ACS Infect Dis. 2021 Jun 11;7(6):1457-1468. doi: 10.1021/acsinfecdis.0c00815. Epub 2021 Feb 11.
7
Multiscale Simulations of the Covalent Inhibition of the SARS-CoV-2 Main Protease: Four Compounds and Three Reaction Mechanisms.多尺度模拟 SARS-CoV-2 主蛋白酶的共价抑制:四种化合物和三种反应机制。
J Am Chem Soc. 2023 Jun 21;145(24):13204-13214. doi: 10.1021/jacs.3c02229. Epub 2023 Jun 9.
8
Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.基于深度学习的筛选发现新型 SARS-CoV-2 3CL 蛋白酶共价抑制剂。
Eur J Med Chem. 2022 Dec 15;244:114803. doi: 10.1016/j.ejmech.2022.114803. Epub 2022 Oct 3.
9
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.含奈玛特韦的 SARS-CoV-2 主蛋白酶抑制剂的炔衍生物通过与亲核半胱氨酸发生共价反应来抑制。
J Med Chem. 2023 Feb 23;66(4):2663-2680. doi: 10.1021/acs.jmedchem.2c01627. Epub 2023 Feb 9.
10
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.青霉素衍生物通过与 SARS-CoV-2 主蛋白酶的亲核半胱氨酸反应来抑制该酶。
J Med Chem. 2022 Jun 9;65(11):7682-7696. doi: 10.1021/acs.jmedchem.1c02214. Epub 2022 May 12.

本文引用的文献

1
Preclinical evaluation of the SARS-CoV-2 M inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.SARS-CoV-2 M 抑制剂 RAY1216 的临床前评估显示其药代动力学特性优于奈玛特韦。
Nat Microbiol. 2024 Apr;9(4):1075-1088. doi: 10.1038/s41564-024-01618-9. Epub 2024 Mar 29.
2
Fusion of Michael-acceptors enhances the anti-inflammatory activity of ginsenosides as potential modulators of the NLRP3 signaling pathway.迈克尔受体的融合增强了人参皂苷作为NLRP3信号通路潜在调节剂的抗炎活性。
Bioorg Chem. 2023 May;134:106467. doi: 10.1016/j.bioorg.2023.106467. Epub 2023 Mar 15.
3
Improvement of the Chemical Reactivity of Michael Acceptor of Ethacrynic Acid Correlates with Antiproliferative Activities.
米开朗基罗受体的丙烯酸盐迈克尔加成物的化学反应性提高与抗增殖活性相关。
Molecules. 2023 Jan 16;28(2):910. doi: 10.3390/molecules28020910.
4
Michael acceptor molecules in natural products and their mechanism of action.天然产物中的迈克尔受体分子及其作用机制。
Front Pharmacol. 2022 Nov 2;13:1033003. doi: 10.3389/fphar.2022.1033003. eCollection 2022.
5
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.靶向 SARS-CoV-2 主蛋白酶治疗 COVID-19:共价抑制剂结构-活性关系的洞察和进化视角。
J Med Chem. 2022 Oct 13;65(19):12500-12534. doi: 10.1021/acs.jmedchem.2c01005. Epub 2022 Sep 28.
6
Paxlovid: Mechanism of Action, Synthesis, and Study.帕克洛维德:作用机制、合成及研究。
Biomed Res Int. 2022 Jul 7;2022:7341493. doi: 10.1155/2022/7341493. eCollection 2022.
7
An orally available M inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron.一种口服 M 抑制剂对野生型 SARS-CoV-2 及其变体(包括奥密克戎)有效。
Nat Microbiol. 2022 May;7(5):716-725. doi: 10.1038/s41564-022-01119-7. Epub 2022 Apr 27.
8
Advances in the Development of SARS-CoV-2 Mpro Inhibitors.SARS-CoV-2 Mpro 抑制剂研发进展。
Molecules. 2022 Apr 14;27(8):2523. doi: 10.3390/molecules27082523.
9
A review of the latest research on M targeting SARS-COV inhibitors.关于靶向严重急性呼吸综合征冠状病毒(SARS-CoV)抑制剂的M的最新研究综述。
RSC Med Chem. 2021 Apr 14;12(7):1026-1036. doi: 10.1039/d1md00066g. eCollection 2021 Jul 21.
10
Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease.可逆共价抑制剂通过靶向3C蛋白酶抑制肠道病毒71型感染。
Antiviral Res. 2021 Aug;192:105102. doi: 10.1016/j.antiviral.2021.105102. Epub 2021 Jun 1.